Background and Objectives: Obstructive sleep apnea (OSA) is associated with sleepiness,
Introduction
Obstructive sleep apnea (OSA) is an important sleep related breathing disorder with prevalence rates between 3-17% in men and 3-9% in women (1, 2) . With the rising trend of obesity, it is becoming increasingly more common (2, 3) . In a number of longitudinal cohort studies, severe OSA is associated with an increased incidence of hypertension, cardiovascular disease and death (4) (5) (6) (7) (8) (9) . It also is adversely associated with a number of neurocognitive and behavioral outcomes including depression (10) , sleepiness (11) , and poor quality of life (12) .
The most commonly used metric to classify severity of OSA is the apnea-hypopnea index (AHI) which is the number of apnea or hypopnea events per hour of sleep. Persons with an AHI < 5 are not considered to have OSA (13) . In contrast, an AHI > 5 and < 15, AHI > 15 and <30, and an AHI > 30 are classified as mild, moderate, and severe respectively (14) . It is generally accepted that OSA can negatively impact mood, wakefulness and quality of life.
However, it is unclear whether mild OSA can have such effects (10, 11, 15) . Epidemiological studies have generally shown that individuals with OSA are sleepier than those without OSA (16) . Existing data in persons with mild OSA referred tp sleep clinics are either limited primarily to assessments of sleepiness or have conflicting results (12, 17, 18) .
The Apnea Positive Pressure Long-term Efficacy Study (APPLES) is a randomized, double-blinded, sham-controlled, multi-center trial of continuous positive airway pressure (CPAP) therapy designed to determine whether CPAP improves neurocognitive function over a 6-month test period (19) . The present study is an analysis of the relationship between assessments of mood, sleepiness and quality of life in those without OSA versus mild OSA at the baseline visit (pre-randomization) in those screened for participation in APPLES. Our intent was to determine whether there was any association between mild OSA and these domains.
Methods

PARTICIPANTS AND STUDY DESIGN:
The study design, recruitment procedures, and inclusion and exclusion criteria for APPLES have been described extensively (19 (14) . At enrollment, participants underwent a screening diagnostic polysomnogram (PSG) and baseline neurocognitive testing including the standardized assessments described below. Only participants with an apnea hypopnea index (AHI) > 10 events per hour continued to the clinical trial and were randomized subsequently to sham or active CPAP for 6 months as previously reported (19) . Excluded were individuals who had 1) prior OSA treatment with CPAP or surgery, 2) household members with current/past CPAP use, 3) a sleepiness-related automobile accident within the year prior to potential enrollment, (4) oxygen saturations < 75% for > 10% of the diagnostic polysomnogram (PSG) total sleep time; or (5) conditions or use of medications that could potentially affect neurocognitive function and/or alertness. For the present analysis, data from both randomized and non randomized participants at the time of the screening polysomnography visit were utilized. In addition to new information, some of the material related to sleepiness reported herein represent reanalysis of data in a different format from what has been published in a previous paper (20) .
POLYSOMNOGRAPHY
Polysomnography was conducted as previously described using signals from a nasal pressure cannula, nasal/oral thermistor, thoracic and abdominal piezo bands, and a pulse oximeter to classify apnea and hypopnea events. An apnea was identified by a > 90% amplitude decrease from baseline of the nasal pressure signal lasting > 10 sec. Hypopneas were scored if there was a > 50%, but < 90% decrease from baseline of the nasal pressure signal, or if there was a clear amplitude reduction of the nasal pressure signal that did not reach the above criterion but it was associated with either an oxygen desaturation > 3% or an arousal, and the event duration was ≥ 10 seconds. Obstructive apneas were identified by persistence of chest or abdominal respiratory effort during flow cessation. Central apneas were noted if no displacement occurred on either the thoracic or abdominal channels. All studies were scored at the central reading center located at Stanford University.
ASSESSMENTS OF SLEEPINESS
Epworth Sleepiness Scale (ESS):
The ESS is a validated self-administered questionnaire that asks an individual to rate his or her probability of falling asleep on a scale of increasing probability from 0 to 3 in 8 different situations (21) . The scores for the 8 questions are summed to obtain a single score from 0 to 24 that is indicative of self-reported sleep propensity. Impact of Mild OSA 6 
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The ESS prior to randomization was administered at the time of the clinical evaluation and on the night of the diagnostic PSG. The value at the time of the diagnostic PSG was used, but if not available, then the value at the time of the clinical evaluation was substituted.
Stanford Sleepiness Scale (SSS):
The SSS asks a person to rate current moment sleepiness on a scale of one to seven (22) . Each numerical rating has an associated descriptor, for example a rating of 1 is described as "feeling active, vital, alert, or wide awake," while a rating of 7 is described as "no longer fighting sleep, sleep onset soon; having dream-like thoughts." For APPLES the SSS was administered at 10:00, 12:00, 14:00, and 16:00 on the day following the diagnostic PSG; the variable analyzed was the mean score from these 4 trials.
ASSESSMENTS OF MOOD:
Profile of Mood States (POMS):
The POMS assesses mood by asking respondents how they feel at that moment according to a series of 65 descriptors such as "unhappy, tense or cheerful" (23) . Possible responses are not at all, a little, moderately; quite a lot, extremely. Six mood states are used in the POMS: tension, depression, anger, vigor, fatigue, and confusion, which can be combined to form the total POMS mood disturbance score. Higher scores represent more negative mood states. For this analysis, total mood disturbance score was used.
Hamilton Rating Scale for Depression (HAM-D):
The HAM-D is a validated 21-item clinician-administered assessment of the severity of depression (24) . APPLES used a modified version of this test, the GRID Hamilton Rating Scale for Depression that was developed through a broad-based international consensus process to both simplify and standardize administration and scoring in clinical practice and research (25) . In this scale, 17 items (e.g., depressed mood, suicide, work and anhedonia, retardation, agitation, gastrointestinal or general somatic symptoms, hypochondriasis, loss of insight or weight) are scored using either a 3-or 5-point scale based on intensity and frequency, and are summed to provide a single score. Higher scores reflect more depressive symptoms. For this analysis, participants who had an AHI < 5 were assigned to the No OSA group, and those who had an AHI > 5, but < 15 were assigned to the Mild OSA group. Body mass index (BMI) was computed as weight (kg)/height (m) 2 . Participants' race/ethnicity were classified as self-reported white or non-white. Marital status was categorized as married or not married.
QUALITY OF LIFE ASSESSMENT:
For continuous variables, unadjusted comparisons between the No OSA and Mild OSA groups were made using Student's t-test. Differences in proportions were assessed using the χ 2 test.
Analysis of covariance was performed to adjust for differences in study site, age and BMI. Data are expressed as mean + standard deviation (SD) or percentages. P < 0.05 was considered statistically significant. Analyses were performed using IBM SPSS Statistics Version 20 (Chicago, IL).
Results
In Table 2 shows the comparisons between the No OSA and Mild OSA groups for the sleepiness, mood and quality of life metrics. There were no statistically significant differences observed for any of these variables. The table also shows the power in this study to detect clinically significant differences in these metrics. As shown, there is 90% power to demonstrate a 1.92, 0.52, 12.72, 1.90 and 0.45 difference between groups in the ESS, SSS, POMS, HAM-D and SAQLI respectively. Furthermore, although the No OSA group was slightly younger, there were no significant correlations between age and the ESS, SSS, POMS, HAM-D, and the SAQLI (r values between 0.04 and 0.11).
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Discussion
In this analysis, we show that using a commonly accepted definition of mild OSA, sleepiness and mood are not different in comparison to persons without significant OSA. Furthermore, there was no evidence that mild OSA negatively impacts quality of life. These data suggest that mild OSA as currently defined has little adverse impact on sleepiness, mood and quality of life.
We observed that there were no differences in the ESS between participants with No OSA in comparison to those with Mild OSA. Results from other large cohorts are conflicting. Our results are consistent with those of Lopes et al who also did not find that the ESS was elevated in those with Mild OSA in a large population of patients undergoing PSG for suspected OSA (12) . In contrast, a cohort of Chinese patients with mild OSA had a greater prevalence of subjective daytime sleepiness in comparison to those with primary snoring (18) . However, the ESS was not higher in contrast to the Sleep Heart Health Study in which the ESS appeared to be greater in those with Mild OSA (16) . Similarly, excessive daytime sleepiness was more commonly reported among a cohort of Japanese women participating in a cardiovascular risk study (17) . In this latter study, OSA status was determined using pulse oximetry and not PSG. A number of other studies also have reported sleepiness data in subjects with mild OSA.
However, small sample sizes, populations with specialized characteristics, and lack of specific comparisons between persons with mild OSA and no OSA limit their interpretability (27) (28) (29) (30) (31) (32) .
In this study, mood as assessed by the POMS and the HAM-D was not worse in the Mild OSA group. Although depressive symptoms and use of anti-depressants are commonly noted among patients with OSA (33) (34) (35) , studies of whether mood is affected by mild OSA are few. In 2 studies performed in patients seen in an otolaryngology clinic (27, 31) , the Beck's Depression Inventory (BDI) was not different in comparison to either a control group or primary snorers.
Similarly, in a group of elderly Koreans referred to a sleep clinic, the BDI was not elevated in comparison to an age-matched control group (36) . Our findings extend these previous reports by showing that using two different assessments of mood, there was no adverse impact of mild OSA.
Quality of life in this study was not affected by mild OSA. In contrast, in a number of studies, quality of life assessed with various instruments is impaired in persons with OSA (37) (38) (39) (40) . However, there are few studies in which the potential impact of mild OSA has been examined. In a relatively small study performed in patients from an otolaryngology clinic, scores on the SAQLI in patients with mild OSA were the same as a group of primary snorers (31) . Fractures cohort, scores on the Functional Outcomes of Sleep Questionnaire were the same across tertiles of OSA severity (41) . Thus, our findings demonstrating a lack of association between mild OSA and quality of life are consistent with these previous studies.
Our failure to demonstrate an association between mild OSA and sleepiness, mood and quality of life provides additional data challenging the commonly used threshold for "defining disease" in the assessment of OSA. The traditional cutpoint of 5 originated more than 30 years ago when only apneic events were scored (42, 43) . In the intervening years, it has been accepted that hypopneas have pathophysiologic significance and are now incorporated into the AHI (44) . Additionally, some clinicians advocate including the more subtle respiratory effort related arousals into a broader respiratory disturbance index (RDI) (45) . The data in this study suggest that at least for some domains of OSA symptomatology, mild OSA based on the application of current scoring criteria to older thresholds may in fact be part of a normal population.
Despite our findings, clinicians, insurers and policy makers should be cautioned about using the AHI as the sole metric in determining whether or not to treat an individual patient. The impact of OSA insofar as behavioral and neurocognitive domains are concerned appears to be quite heterogeneous. For example, 54% of individuals in the Sleep Heart Health Study with moderate to severe OSA were not sleepy on any one of 3 measures of sleepiness. Conversely, some individuals with less severe OSA may be sleepy (16) . In our study, the mean ESS in both the No OSA and Mild OSA groups was above what would be expected for an unselected general population suggesting that other causes of sleepiness were present in the cohort (16) .
Thus, before deciding to initiate OSA specific treatment for Mild OSA, clinicians should consider whether there are other explanations for the patient's symptoms, and not just treat the AHI.
This study does have three major limitations. First, it might be argued that our study was underpowered to detect small differences between the No OSA and Mild OSA groups. However, sufficient statistical power was present to detect clinically important differences ( Table 2) . For example, it has been proposed that the minimally important difference on repeated administrations of the SAQLI is approximately 1 (46) . Our results demonstrated that we had 90% power to detect a change of 0.5. Moreover, our findings are consistent with the limited number of studies previously performed. Second, our participants were a mixture of individuals recruited from sleep clinics and those responding to advertisements. Thus, they may not be representative of the general populace. Third, it is possible that the No OSA group included Impact of Mild OSA 10 Quan et al some individuals who actually had mild OSA. Inasmuch as all participants were considered by clinicians to have symptoms consistent with OSA, some individuals in the No OSA group may have had falsely "negative" PSGs. Such misclassification would bias towards a null effect. The extent to which this occurred is not known, but night to night variability of the AHI is relatively low (47) . Thus, we suspect this potential bias is small. Despite these limitations, however, the APPLES cohort was geographically and ethnically diverse, and had a representative gender distribution.
In conclusion, evidence from this analysis does not indicate that mild OSA has any impact on sleepiness, mood or quality of life. This raises concerns whether the current AHI criteria for distinguishing mild OSA from no clinically significant OSA needs to be reassessed.
Nevertheless, additional comparisons between individuals who are truly without OSA symptoms and those with mild OSA as currently defined need to be performed before a final conclusion can be determined. 
